ID   B16-F10
AC   CVCL_0159
SY   B16/F10; B16 F10; B16F10; B16 melanoma F10
DR   BTO; BTO:0002014
DR   CLO; CLO_0001794
DR   CLO; CLO_0050763
DR   MCCL; MCC:0000051
DR   CLDB; cl339
DR   CLDB; cl4967
DR   AddexBio; C0012005/5003
DR   ATCC; CRL-6475
DR   BCRC; 60031
DR   BCRJ; 0046
DR   CCRID; 3111C0001CCC000473
DR   CCRID; 3131C0001000800036
DR   ChEMBL-Cells; CHEMBL3307762
DR   ChEMBL-Targets; CHEMBL612656
DR   ICLC; ATL99010
DR   KCB; KCB 2014047YJ
DR   KCLB; 80008
DR   Lonza; 998
DR   NCBI_Iran; C540
DR   NCI-DTP; B16F10
DR   PRIDE; PXD008733
DR   RCB; RCB2630
DR   TKG; TKG 0348
DR   Wikidata; Q54752438
RX   PubMed=210294;
RX   PubMed=1109790;
RX   PubMed=6539703;
RX   PubMed=11833741;
RX   PubMed=23890195;
RX   PubMed=25277546;
RX   PubMed=30084848;
CC   Characteristics: Obtained from the pulmonary melanoma module of the 10th serial passage of the B16-F0 parent cell line in C57BL/6 mice.
CC   Characteristics: Has a high metastatic potential.
CC   Doubling time: 17 hours (PubMed=1109790); 17.2 hours (PubMed=23890195).
CC   Omics: HLA class I peptidome analysis by proteomics.
CC   Omics: SNP array analysis.
CC   Breed/subspecies: C57BL/6.
DI   NCIt; C21790; Mouse melanoma
OX   NCBI_TaxID=10090; ! Mus musculus
HI   CVCL_UJ41 ! B16-F5
SX   Male
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-07-20; Version: 22
RX   PubMed=210294; DOI=10.1093/jnci/61.2.523;
RA   Niles R.M., Makarski J.S.;
RT   "Control of melanogenesis in mouse melanoma cells of varying
RT   metastatic potential.";
RL   J. Natl. Cancer Inst. 61:523-526(1978).
RX   PubMed=1109790;
RA   Fidler I.J.;
RT   "Biological behavior of malignant melanoma cells correlated to their
RT   survival in vivo.";
RL   Cancer Res. 35:218-224(1975).
RX   PubMed=6539703; DOI=10.1016/0277-5379(84)90015-4;
RA   Weinreb A., Travo P.;
RT   "Discrimination between human melanoma cell lines by fluorescence
RT   anisotropy.";
RL   Eur. J. Cancer Clin. Oncol. 20:673-677(1984).
RX   PubMed=11833741; DOI=10.1016/S0024-3205(01)01454-0;
RA   Nakamura K., Yoshikawa N., Yamaguchi Y., Kagota S., Shinozuka K.,
RA   Kunitomo M.;
RT   "Characterization of mouse melanoma cell lines by their mortal
RT   malignancy using an experimental metastatic model.";
RL   Life Sci. 70:791-798(2002).
RX   PubMed=23890195; DOI=10.1186/1475-2867-13-75;
RA   Danciu C., Falamas A., Dehelean C., Soica C., Radeke H.,
RA   Barbu-Tudoran L., Bojin F., Pinzaru S.C.;
RT   "A characterization of four B16 murine melanoma cell sublines
RT   molecular fingerprint and proliferation behavior.";
RL   Cancer Cell Int. 13:75-75(2013).
RX   PubMed=25277546; DOI=10.1186/1471-2164-15-847;
RA   Didion J.P., Buus R.J., Naghashfar Z., Threadgill D.W.,
RA   Morse H.C. III, de Villena F.P.;
RT   "SNP array profiling of mouse cell lines identifies their strains of
RT   origin and reveals cross-contamination and widespread aneuploidy.";
RL   BMC Genomics 15:847-847(2014).
RX   PubMed=30084848; DOI=10.1038/sdata.2018.157;
RA   Schuster H., Shao W., Weiss T., Pedrioli P.G.A., Roth P., Weller M.,
RA   Campbell D.S., Deutsch E.W., Moritz R.L., Planz O., Rammensee H.-G.,
RA   Aebersold R., Caron E.;
RT   "A tissue-based draft map of the murine MHC class I immunopeptidome.";
RL   Sci. Data 5:180157-180157(2018).